Biocodex SAS

11/05/2026 | Press release | Distributed by Public on 11/05/2026 02:55

Biocodex strengthens its industrial capabilities in microbiome-based live biotherapeutics with a new dedicated platform

Biocodex, a French pharmaceutical company, announces a €15 million investment to develop a new industrial platform dedicated to microbiome-based Live Biotherapeutic Products (LBPs) at its Beauvais manufacturing site in France.
Biocodex SAS published this content on November 05, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 05, 2026 at 08:55 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]